In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.

• Egile Nagusiak: Adriano C Coelho (Egilea), Cristiana T Trinconi (Egilea), Carlos H N Costa (Egilea), Silvia R B Uliana (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2014-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented. Leishmania amazonensis is the second most prevalent species causing cutaneous leishmaniasis and the main etiological agent of diffuse cutan...